Science Shop
AdvertisementUK Approves CRISPR/Cas Drug Casgevy for Blood Disorders
The UK’s MHRA has greenlit Casgevy, a CRISPR/Cas gene-editing drug, for treating blood disorders. This groundbreaking approval offers hope to patients aged twelve and above